Key result
Patients with Brugada syndrome had a higher rate of S-ICD screening failure compared with other cardiac channelopathies, primarily due to high T wave voltages.
Why the study?
Does Brugada syndrome increase the rate of S-ICD sensing screening failure compared to other inherited primary arrhythmia syndromes?
Observational (n=100)
Does Brugada syndrome increase the rate of S-ICD sensing screening failure compared to other inherited primary arrhythmia syndromes?
Patients with Brugada syndrome have a higher rate of S-ICD screening failure compared to other channelopathies, primarily due to high T wave voltages, highlighting the need for careful pre-implantation screening including drug challenge.
Answers are grounded in this paper and cite their sources.
May warrant extra screening caution in Brugada syndrome; leaves open whether syndrome-specific S-ICD criteria are needed.
Aims: Subcutaneous implantable cardioverter-defibrillator (S-ICD) can avoid important complications associated with transvenous leads in patients with inherited primary arrhythmia syndromes, who do not need pacing therapy. Few data are available on the percentage of patients with inherited arrhythmia syndromes eligible for S-ICD implantation. Aim of this study was to analyse the eligibility for S-ICD in a series of patients with Brugada syndrome (BrS), and to compare it with patients with other channelopathies. Methods and results: Patients presenting with BrS, long-QT syndrome (LQTS), early repolarization syndrome (ERS), and idiopathic ventricular fibrillation (IVF) were considered eligible for this study. ECG screening was performed by analysis of QRS complex and T wave morphology recorded in standing and supine position. Eligibility was defined when ≥1 sense vector was acceptable in both supine and standing position. A total of 100 patients (72 males; mean age: 46 ± 17 years) underwent S-ICD sensing screening. Sixty-one patients presented with BrS, 21 with LQTS, 14 with IVF, and 4 with ERS. Thirty-four patients with BrS (56%) presented with spontaneous type 1 ECG. In the other 27 patients (44%), type 1 ECG was unmasked by ajmaline. Overall, rate of screening failure was 13%. Patients with BrS had a higher rate of inappropriate morphology analysis as compared with other channelopathies (18% vs. 5%, P = 0.07) and had a lower number of suitable sensing vectors (49.6% vs. 84.7% vs. P < 0.001). Ajmaline challenge unmasked sensing failure in 14.8% of drug-induced BrS patients previously considered eligible. In all patients, the reason for sensing inappropriateness was due to the presence of high T wave voltages. Conclusion: S-ICD screening failure occurs in up to 13% of patients with inherited primary arrhythmia syndromes. Patients with BrS present a higher rate of screening failure as compared with other cardiac channelopathies.
No takes yet. Share an insight, caveat, or question.
Conte et al. (2017) conducted an observational in Inherited primary arrhythmia syndromes (n=100). Brugada syndrome vs. Other cardiac channelopathies (LQTS, ERS, IVF) was evaluated on Inappropriate morphology analysis (S-ICD screening failure) (p=0.07). Patients with Brugada syndrome had a higher rate of S-ICD screening failure compared with other cardiac channelopathies, primarily due to high T wave voltages.
Synapse has enriched 10 related papers. Consider them for comparative context: